secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pacira BioSciences, Inc. (PCRX)
CIK:        0001396814
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001396814-23-000008
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pacira BioSciences reports record 2022 revenue of $667M; Q4 GAAP net loss widens to $10.1M
--------------------------------------------------------------------------------

- Full-year 2022 revenue $666.8M (+23% YoY); GAAP net income $15.9M ($0.34 diluted EPS) vs $42.0M ($0.92) in 2021.
- Q4 2022 revenue $172.0M (+8% YoY); GAAP net loss $10.1M ($0.22 loss per share) vs loss $5.1M in Q4 2021.
- ZILRETTA net sales $105.5M full year; Q4 $28.0M (+121% YoY) driving growth. EXPAREL $536.9M (+6%) full year; Q4 $138.0M (-1%).
- 2023 guidance: EXPAREL net sales $570-580M, ZILRETTA $115-125M, non-GAAP gross margin 76-78%.
- Submitted sNDA for EXPAREL sciatic/femoral nerve blocks; opened Houston Innovation & Training Center in Jan 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1396814/000139681423000008/0001396814-23-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1396814/000139681423000008/pcrx-20230228.htm
  HTML page:      https://secwatch.observer/filing/0001396814-23-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer